Table 4.
Comparison of Induction Mortality Rates and Resource Utilization Between Those Receiving Antimold Prophylaxis and Those Receiving Fluconazole Prophylaxis
| Resource | Antimold Prophylaxis (n = 99) | Fluconazole Prophylaxis (n = 396) | Unadjusted IRR (95% CI) | Adjusted IRR (95% CI) |
|---|---|---|---|---|
| Death during induction, No. (%) | 4 (4.0) | 8 (2.0) | 1.0a (.39–5.62) | 0.78a (.11–5.66) |
| Specific resources, days exposed per 1000 study days | ||||
| Broad gram-positive coverageb | 251.0 | 207.1 | 1.21 (1.04–1.72) | 1.02 (.80–1.29) |
| β-lactam anti-Pseudomonas coveragec | 445.4 | 398.4 | 1.12 (1.02–1.23) | 0.91 (.78–1.05) |
| Blood culture | 135.5 | 137.3 | 0.99 (.85–1.15) | 0.93 (.74–1.17) |
| Chest CT scan | 10.07 | 12.18 | 0.83 (.59–1.15) | 0.66 (.41–1.08) |
Abbreviations: CT, computed tomography; IRR, incidence rate ratio.
a Values shown are hazard ratios; adjusted using propensity score and mean use of prophylaxis type by hospital.
b Includes vancomycin, linezolid, daptomycin, and quinupristin/dalfopristin.
c Includes ceftazidime, cefepime, piperacillin/tazobactam, ticarcillin/clavulanate, meropenem, imipenem, and aztreonam.